Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T4020 versus vehicle for chronic neurotrophic keratitis or corneal ulcer
NL-OMON44908Phase 3Active, not recruiting
- Sponsor
- Laboratoires Théa
- Start
- Nov 2013
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neurotrophic keratitis (NK) and corneal ulcer comparing T4020 with Vehicle (2 arms). Primary endpoint: Primary efficacy responder rate at Day 28. Started Nov 2013; status: active, not recruiting.
02
Drugs
Cacicol 20
03
Conditions
neurotrophic keratitis (NK)corneal ulcer
Beyond the preview
Go deeper on NL-OMON44908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44908.